CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief...